ECE2022 Eposter Presentations Calcium and Bone (114 abstracts)
1Leiden University Medical Centre, Department of Medicine, Division of Endocrinology, Leiden, Netherlands; 2University of Glasgow, Office for rare Conditions, Glasgow, UK; 3Fondazione Italiana Ricerca Sulle Malattie DellOsso (F.I.R.M.O. Foundation), Florence, Italy; 4Hebrew University, Neuroendocrine Unit, Enets Center of Excellence, Department of Endocrinology and Metabolism, Hadassah Medical Organization and Faculty of Medicine, Jerusalem, Israel; 5Irccs Istituto Ortopedico Rizzoli, Department of Rare Skeletal Disorders, Bologna, Italy; 6University of Helsinki and Helsinki University Hospital, Division of Endocrinology, Abdominal Center, Helsinki, Finland; 7Erasmus Mc Sophia Childrens Hospital, University Medical center Rotterdam, Division of Pediatric Endocrinology, Department 0f Pediatrics, Rotterdam, Netherlands; 8University of glasgow, Developmental Endocrinology Research Group, Royal Hospital for Children, Glasgow, UK.
Background The European Registries for Rare Endocrine Conditions and the European Registries for Rare Bone and Mineral Conditions were created in collaboration with the European Reference Networks for Rare Endocrine and Bone Disorders (Endo-ERN and ERN BOND). Following the onset of the COVID-19 pandemic in 2020, the registries, together with the ESE RD Committee, have collected the occurrence of confirmed and suspected cases of COVID-19 in patients with rare endocrine and bone conditions via the electronic reporting system (e-REC), a tool that does not collect personal identifiable information.
Aim To collect clinical outcome data of patients with rare bone and mineral disorders affected by COVID-19.
Methods Between May 2020 and May 2021, 11 cases of COVID-19 in patients with a preexisting mineral condition and 8 in patients with a preexisting bone condition were reported. Reporters were invited to complete a secure online questionnaire. The questionnaire was completed in 15/19 cases (79%) from four centres in three countries. Of 19 cases, 18(95%) were confirmed by a test. Vaccination status was reported only for one case of mineral conditions (1/19), who had received the vaccine.
Results Of 7 mineral cases, 3 had hypophosphatemia (42%), 3 hypoparathyroidism (42%) and 1 primary hyperparathyroidism (14%). The median age at the time of infection was 39 (range 4,52). Of 7 cases 6 were confirmed by a test (86%). The most prevalent symptoms were fever 5/7 (71%), cough 3/7 (43%), fatigue 3/7 (43%), loss of taste and smell 3/7 (43%), muscle pain 3/7 (43%), runny nose 2/7 (28%), headache 2/7 (28%) and shortness of breath 2/7 (28%). One patient was asymptomatic. Comorbidities were reported in 4/7 (57%): hypertension 2/7 (28%), obesity 1/7 (14%), asthma 1/7 (14%). None required hospital admission and complete remission occurred in all cases. Of 8 bone cases 5 had fibrous dysplasia of bone (62%), 2/8 (25%) had a bone dysplasia with increased bone density and 1/7 (13%) had osteogenesis imperfecta. The median age at the time of the COVID-19 infection was 35 (range 16,69). The most prevalent symptoms were cough 6/8 (75%), fever 4/8 (50%), and shortness of breath 2/8 (25%). Two patients were asymptomatic (25%). Comorbidities were reported in 3/8 (38%): obesity 2/7 (25%) and asthma 1/8 (13%). None required hospital admission and complete remission occurred in 100% of cases.
Conclusion The results of this survey suggest good clinical outcomes in patients with rare bone and mineral disorders experiencing a COVID-19 infection.